EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasionCRL3KEAP1 targets EMSY for degradation to regulate genome stability and the type I interferon response, suggesting that PARP inhibitors and STING agonists hold therapeutic potential for the treatment of KEAP1-mutant lung cancers.CRL3KEAP1 targets EMSY for degradation to regulate genome stability and the type I interferon response, suggesting that PARP inhibitors and STING agonists hold therapeutic potential for the treatment of KEAP1-mutant lung cancers.Antonio Marzio, Emma Kurz, Jennifer M. Sahni, Giuseppe Di Feo, Joseph Puccini, Shaowen Jiang, Carolina Alcantara Hirsch, Arnaldo A. Arbini, Warren L. Wu, Harvey I. Pass, Dafna Bar-Sagi, Thales Papagiannakopoulos, Michele Paganohttps://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2821%2901427-6%3Frss%3Dyes&rc=0http://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignDecember 28, 2021

Powered by WPeMatico